Want to see more of NewsNation? Get 24/7 fact-based news coverage with the NewsNation app or add NewsNation as a preferred source on Google !

( NewsNation ) — Novo Nordisk announced Monday that in two closely watched studies, an oral version of semaglutide failed to help slow the progression of Alzheimer’s .

The trials, which involved more than 3,800 early-stage patients, assessed changes in memory and daily functioning over two years. They also evaluated whether an older semaglutide formulation was more effective than placebo.

The two Phase 3 trials, which tested whether the drug could slow cognitive decline in thousands of patients with mild symptoms, did show an effect on Alzheimer’s biomarkers — though Novo didn’t specify which ones — but the treatment

See Full Page